LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. (Q54350386)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. |
scientific article |
Statements
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. (English)
1 reference
Rosario Pivonello
1 reference
Xavier Bertagna
1 reference
Maria Fleseriu
1 reference
Yiming Zhang
1 reference
Paul Robinson
1 reference
Ann Taylor
1 reference
Catherine E Watson
1 reference
Mario Maldonado
1 reference
Amir H Hamrahian
1 reference
Marco Boscaro
1 reference
Beverly M K Biller
1 reference
11 December 2013
1 reference
99
1 reference
1375-1383
1 reference
4
1 reference
Identifiers
1 reference